At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 270 enrolled
Drug / intervention
mRNA-1010 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age
In Brief
A Phase 2 clinical trial evaluating mRNA-1010, mRNA-1010.4, and 1 other intervention for Influenza. Completed, enrolled 270 participants across 10 sites.
Detailed Summary
The main purpose of the study is to evaluate the safety, reactogenicity, and the immunogenicity of mRNA-1010 vaccine candidate variations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartMay 2023
First PostedMay 2023
Primary CompletionDec 2023
TodayJul 2026
First PostedMay 22, 2023
Enrollment StartMay 15, 2023
Primary CompletionDec 19, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.1 years ago
Interventions
mRNA-1010biological
Sterile liquid for injection
mRNA-1010.4biological
Sterile liquid for injection
mRNA-1010.6biological
Sterile liquid for injection